Gene therapy takes on HIV and cancer in one shot
NCT ID NCT02797470
First seen Jun 03, 2026 · Last updated Jun 23, 2026 · Updated 5 times
Summary
This early-phase trial tests a gene therapy approach for people with HIV who also have lymphoma that has returned or not responded to treatment. Researchers take the patient's own stem cells, add anti-HIV genes in the lab, and return them after a stem cell transplant. The goal is to see if this is safe and if the modified cells can resist HIV infection. Only 11 participants are enrolled, so results are very preliminary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UCSF Medical Center-Parnassus
San Francisco, California, 94115, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gene-modified stem cells (anti-HIV genes)
What this could lead to
If successful, this could point toward a way to make immune cells resistant to HIV, potentially reducing the need for lifelong antiviral drugs.
What could go wrong
This is a very early, small study (11 people) focused on safety. The gene therapy may not work as hoped, and there are risks from the stem cell transplant and chemotherapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.